Last reviewed · How we verify
NCT03710616
A Real-world Study to Explore Recurrence/Metastases of the NSCLC Patients and the Impact Factors of Patient Survivals
trial testing Surgeries in Non-small Cell Lung Cancer in 700 participants. Status unknown.
30 December 2022
Quick facts
| Lead sponsor | The First Affiliated Hospital of Guangzhou Medical University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 700 |
| Start date | 24 March 2018 |
| Primary completion | 30 December 2022 |
| Estimated completion | 1 January 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- Surgeries
Conditions studied
- Non-small Cell Lung Cancer — all drugs for Non-small Cell Lung Cancer →
Sponsor
The First Affiliated Hospital of Guangzhou Medical University
Who can join
Eligibility, any sex, with Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The real-world study was designed to explore recurrence/metastases of the patients with non-small cell lung cancer as measured by patient survivals and the impact factors of patient survivals.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03710616
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Surgeries
Trials testing the same drug.
- NCT04830826 — A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China · completed
- NCT03427541 — A Study to Explore Prognoses of NSCLC Patients Complicated With Oligometastases · unknown
- NCT03415815 — An Observational Study to Evaluate Lymph Metastases and Prognoses of the Patients With Esophageal Cancer · unknown
- NCT03451526 — A Study to Explore Prognoses of the Patients With N2 Non-small Cell Lung Cancer · completed
- NCT03413956 — An Observational Study to Explore Clinical Characteristics of the Patients With T1 Non-small Cell Lung Cancer · completed
Other recruiting trials for Non-small Cell Lung Cancer
Currently open trials in the same condition.
- NCT07431827 — MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) · Phase 3 · recruiting
- NCT05987956 — Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms · Phase 2, PHASE3 · active not recruiting
- NCT07195695 — Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer Wit · Phase 3 · recruiting
- NCT06686771 — Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer · Phase 3 · recruiting
- NCT06477055 — The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer · recruiting
Other The First Affiliated Hospital of Guangzhou Medical University trials
Trials by the same sponsor.
- NCT07413952 — Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases · Phase 2 · not yet recruiting
- NCT07395375 — Non-intubated Versus Intubated Anesthesia for Thoracoscopic Sublobar Resection · NA · not yet recruiting
- NCT07395362 — Hybrid Robot-Assisted Percutaneous Ablation and Non-Intubated VATS for Multiple Pulmonary Nodules · NA · not yet recruiting
- NCT07395349 — Safety And Recovery Of Tubeless Strategy In Uniportal VATS Wedge Resection · NA · not yet recruiting
- NCT07377916 — Clinical Study of SHR-A1811 Combined With Pertuzumab as Second-Line Therapy in Patients With HER2-Altered Advanced NSCLC · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03710616 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Guangzhou Medical University
- Last refreshed: 1 August 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03710616.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing